BLOG

What Japan’s Regenerative Medicine Rules Mean for Stem Cell Patients

Published 2026.10.23 7 min read

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are considering adipose-derived stem cell therapy in Japan, you will quickly notice that the treatment is described as being provided under a legal framework for regenerative medicine. For an international patient, that phrase can feel abstract. This article explains, in plain terms, what a regenerative medicine provision plan means, what it does and does not tell you, and which questions are worth bringing to a consultation at Grand Green Osaka Umekita Clinic in Osaka.

The short answer: a legal framework is a starting point, not a guarantee

In Japan, treatments that use cultured human cells are handled under a system built around the Act on the Safety of Regenerative Medicine. Under this system, a clinic that offers cell-based treatment is expected to prepare a provision plan for that specific treatment and to manage its procedures according to the rules that apply. The clinic describes its adipose-derived stem cell therapy as being provided under such a plan.

It is important to read this correctly. A provision plan indicates that a treatment is offered within a defined safety-management structure. It does not mean that the treatment is guaranteed to work, and it does not replace the individual judgment of your doctor. Whether the treatment is appropriate for you must be decided at a medical consultation.

How the treatment itself works

Adipose-derived stem cell therapy is a regenerative approach in which mesenchymal stem cells are taken from your own fat tissue. According to the clinic, only a very small amount of fat is collected, in an outpatient setting under local anesthesia. The cells are then cultured and expanded at a specialized facility and returned to your body by intravenous infusion.

Mesenchymal stem cells are somatic stem cells found in fat tissue, bone marrow and other sources. Laboratory and clinical research has reported that they may release anti-inflammatory substances and growth factors that support tissue repair. Research in this field is still developing, and results reported in studies cannot be assumed to apply to every individual. Because the cells come from your own body, the treatment is described as autologous, which is one reason the clinic points to a lower risk of rejection than with donor cells.

What the framework means for you as an international patient

Understanding the system helps you ask better questions. A few practical points are worth keeping in mind.

The treatment is offered as a self-pay (non-insured) medical service, so it is not covered by Japan’s public health insurance.
Costs, the number of sessions, risks and possible side effects are explained by the doctor and should be confirmed in writing before you decide.
The provision plan is specific to the treatment offered by the clinic. A plan for one therapy does not automatically cover a different cell type or a different route of administration.
The framework is a Japanese system. Rules in your home country may differ, including how your own doctor views treatment received abroad.

Because regulations and plans can be updated, it is reasonable to ask the clinic how the current provision plan applies to the treatment you are considering, and what information they can share with you in a language you understand.

Questions to bring to your consultation

Rather than asking only whether the treatment is allowed, try to understand how it is managed. The following questions can make a consultation more productive.

Which condition or concern am I being evaluated for, and is this treatment a reasonable option for me or only one of several?
How does this treatment relate to standard medical care for my condition, and should I continue my current treatment?
What are the known risks of fat collection and of intravenous infusion, and what side effects should I watch for afterward?
What is the total cost, what does it include, and are there additional charges for follow-up?
How will my health be monitored after the infusion, and who can I contact if I return to my home country?
Can I receive written information in English, and can an interpreter be arranged?

Bring your medical history, a list of current medications and any recent test results. If you have a doctor at home, consider asking for their view before you travel. This treatment is not a replacement for standard care, and the consultation is the place to discuss how it might fit alongside it.

Planning from overseas and next steps

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka. The clinic provides an information page for international patients, and you can use the web or LINE contact options to ask about the consultation process before you arrive.

Taking time to understand the legal framework, the treatment flow and the fee structure will help you decide calmly. If the treatment is not suitable for you, or if you decide not to proceed, that is a perfectly reasonable outcome of a consultation.

It can also help to write down your own goals before the visit. Some patients are interested in the idea of supporting tissues affected by aging or inflammation, while others simply want to understand their options. Being clear about what you hope to learn will make it easier for the doctor to explain what is realistic, what remains uncertain, and whether another approach, including standard medical care, may be more suitable for your situation.

Summary

Japan’s regenerative medicine framework gives adipose-derived stem cell therapy a defined structure for safety management, but it does not promise results. The therapy is a self-pay treatment, and its suitability, risks, side effects and costs must be confirmed with a doctor after an individual examination. Use the framework as a guide for the questions you ask, and consider consulting the clinic through its pages for international patients before making any decision.

Questions Before You Decide

Know the frameworkNot a guarantee of results
Consult a doctorSuitability is decided there
Ask about risksIncluding side effects
Confirm self-pay costs

This diagram is a conceptual summary of the article

Learn more about Adipose-Derived Stem Cell Therapy

References

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.

Back to article list › Back to Adipose-Derived Stem Cell Therapy ›